Dr. Mark Socinski from the University of Pittsburgh reviews evidence to support doublet chemo over single agent for marginal performance status (PS2) patients with advanced NSCLC.

ASCO 2012 LC Highlights: Dr. Mark Socinski on Single Agent vs Doublet Chemo for PS2 (audio)

Oncology experts summarize current and emerging issues in cancer management for patients and caregivers. Information from the Global Resource for Advancing Cancer Education (GRACE) helps people to become informed partners in their care.

Share ASCO 2012 LC Highlights: Dr. Mark Socinski on Single Agent vs Doublet Chemo for PS2 (audio)

Sign up to save your podcasts

ASCO 2012 LC Highlights: Dr. Mark Socinski on Single Agent vs Doublet Chemo for PS2 (audio)

ASCO 2012 LC Highlights: Dr. Mark Socinski on Single Agent vs Doublet Chemo for PS2 (audio)

More shows like GRACEcast Lung Cancer Audio

GRACEcast Head and Neck Cancer Audio

GRACEcast Lung Cancer Video

GRACEcast Radiation Oncology Audio

GRACEcast Pancreatic Cancer Audio

GRACEcast Pancreatic Cancer Video

GRACEcast Kidney Cancer Video

GRACEcast Cancer 101 Audio

GRACEcast Bladder Cancer Video

GRACEcast Head and Neck Cancer Video NEW

GRACEcast Cancer 101 Video